Novo Nordisk's success with drugs like Ozempic, driven by GLP 1, has made it a major player. This success in the weight loss medication market has caught the attention of the business and finance worlds, impacting stocks. But recently Novo Nordisk (NVO) wiped 25% off its market cap — spooking retail investors, triggering analyst downgrades, and raising one question:Is this a crash… or a generational opportunity?In this episode, we break down:🔹 Why Novo Nordisk stock dropped despite GLP-1 dominance🔹 The growing competition from Eli Lilly & new weight-loss drug wars🔹 Whether Ozempic & Wegovy growth can still fuel future earnings🔹 The valuation reset — bubble pop or healthy correction?🔹 What 2025 could look like for NVO investorsIs this the dip smart money buys, or a sign the hype cycle is over?

00:00 Intro

02:00 NVO Core Business

02:48 Ozempic Boom

03:27 NVO Financials

04:50 Risks & Competition

06:18 Q3 2025 Financials

07:40 NVO Stock Forecast

10:15 Investor Takeaway🔔 Facts Not Forecast delivers data-driven stock market and AI tech insights to help investors spot hidden opportunities. Subscribe for more.👇 Share your thoughts in the comments — which stock do you want us to cover next?#NovoNordisk #NVO #Ozempic #Wegovy #GLP1 #EliLilly #StockMarket #Investing #BiotechStocks #BuyTheDip #StocksToWatch #LongTermInvesting #FactsNotForecastYouTube Channel:youtube.com/@FactsNotForecast